Tempus AI
TEM | NASDAQ
$64.76
-$6.84 (-9.55%)
At close: Nov 16, 2026, 4:00 PM ET
$66.85
+$2.09 (+3.23%)
After-hours:
Nov 16, 2026, 7:59 PM ET
Tempus AI Company Profile
Company profile explainedCompany Profile
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Key Executives
| Name | Position |
|---|---|
| Eric Lefkofsky | Co-Founder, Chief Executive Officer, President & Chairman |
| Ryan Fukushima | Chief Executive Officer of Data & Apps |
| Andrew Polovin | Chief Legal Officer |
| James Rogers | Chief Financial Officer |
| Shane Colley | Chief Technology Officer |
| Stacey Kraft | Chief People Officer |
| Christina Antoniou | Senior Vice President & Head of Corporate Development |
| Elizabeth Krutoholow | Vice President of Investor Relations & Competitive Intelligence |
| Erik Phelps | Executive VP and Chief Administrative & Legal Officer |
| Kate A. Sasser | Chief Scientific Officer |
| Ryan Bartolucci | Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 4 | Filing |
| Oct 28, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 23, 2026 | 8-K | Current Report |
| Oct 21, 2026 | EFFECT | Filing |
| Oct 21, 2026 | 424B3 | Filing |
| Oct 20, 2026 | S-4/A | [Amend] Filing |
| Oct 02, 2026 | S-4/A | [Amend] Filing |
| Sep 29, 2026 | 4 | Filing |
| Sep 24, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
Tempus AI
| Country | United States |
| IPO Date | Jun 14, 2024 |
| Industry | Medical - Healthcare Information Services |
| Sector | Healthcare |
| Employees | 3,800 |
| CEO | Eric Lefkofsky |
Contact Details
600 West Chicago Avenue Chicago,
Illinois 60654 United States
Stock Details
| Ticker Symbol | TEM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001717115 |
| CUSIP Number | 88023B103 |
| ISIN Number | US88023B1035 |
| SIC Code | 7370 |
Recent News
- 4 days ago / newsfilecorp.comArizona Eagle Mining Corp. Announces Completion of High Resolution TEM Geophysical Survey at the Eagle Project and Provides Update on McCabe Mine Reopening Studies
- 5 days ago / businesswire.comTempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual Meeting
- 6 days ago / prnewswire.comBlood Cancer United Launches REALworld: AML to Accelerate New Treatments for Children with Blood Cancer
- 7 days ago / prnewswire.comSOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer
- 9 days ago / seekingalpha.comTempus AI: Q3 Strengthens The Platform Thesis, But Cash Returns Still Need To Catch Up
- 13 days ago / seekingalpha.comTempus AI: An Inflection Point Has Arrived (Earnings Analysis)
- 14 days ago / marketbeat.comTempus AI Surges on Earnings Beat, But Can the Rally Last?
- 14 days ago / zacks.comTEM Q3 Earnings Call Highlights Growth and 2027 Pricing Upside
- 14 days ago / benzinga.comTempus AI Analysts Boost Their Forecasts Following Strong Q3 Results
- 14 days ago / 247wallst.comDo You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings Surge
Add to Watchlist
Select watchlists to add or remove TEM